Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Spinout Syntopix announces new funding deal

28.10.2004


University of Leeds life sciences company Syntopix Ltd has secured further capital of just under £180,000 through a consortium of regional investors.

Formed in 2003, Syntopix is based on the leading research of husband and wife team Drs Jon Cove and Anne Eady, both microbiologists in the University’s Skin Research Centre. Their work focuses on developing novel therapeutics for dermatological diseases, including acne and Staphylococcus aureus infections such as the ‘superbug’ MRSA.

The deal, announced this week, sees investment from a consortium comprising: Techtran Group Ltd, regional venture capital funds the White Rose Technology Seedcorn Fund and the Viking Fund, and business angels Dr Gwyn Humphreys and Dr Rod Adams.



Dr Humphreys has been appointed as the company’s new chairman and Dr Adams joins Syntopix as a non-executive director. Both have successful track records in growing businesses in the pharmaceutical industry. Dr Humphreys was joint founder / CEO of Bradford Particle Design, sold to Inhale Therapeutics in 2001 for $200m and Dr Adams was formerly CEO of Medical Solutions plc and local dermatology company Adams Healthcare. Dr Alex Stevenson has joined the company as Chief Executive Officer.

Syntopix was spun out by Techtran Group, the commercialisation partner of the University of Leeds, and the science underpinning the company was initially funded with £500,000 from the Wellcome Trust. The company’s approach is to generate new therapeutic products for target diseases by identifying novel combinations of compounds which together deliver new therapeutic benefits. Since the majority of the compounds used already have well-documented pharmacology and toxicity profiles and are already established as safe for human use, the development cycle of new products can be substantially reduced, saving both time and money. The company is rapidly developing a pipeline of its own drug candidates, and expects to commence clinical trials of its lead candidates in the next two to three years.

In addition the company offers contract testing and expert consultancy in pre-clinical and clinical drug development. A number of contracts with partners in the dermatology arena are already in place. The new funding strengthens the management structure, increases the research team to six and will accelerate the development of anti-acne products.

Syntopix CEO Dr Alex Stevenson said: “We are delighted to have received the backing of such a broad range of regional investors and look forward to bringing the results of our research to the clinic.”

The White Rose Technology Seedcorn Fund has to date invested in nineteen spinout companies from the Universities of Leeds, Sheffield and York. Investment Manager, Dr Susan Hill, said: “We were attracted to Syntopix’ considerable expertise in the field of skin diseases, which includes a number of significant markets, and the company’s approach to product development. We look forward to working with the team to deliver on its exciting potential.”

The investment is the first for the Viking Fund, which was established in June to provide seed capital for technology-based early stage companies in the Yorkshire and Humber region. Viking Fund managing director Andrew Burton said: “Syntopix is fairly typical of early-stage, technology businesses in which Viking Fund is looking to invest. It has high quality science, a simple commercial model, experienced people and ready matching investment.”

Dr Alex Stevenson | alfa
Further information:
http://www.syntopix.com

More articles from Life Sciences:

nachricht Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH

nachricht Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>